Addendum
Ribociclib (breast cancer, adjuvant treatment) – Addendum to Project A24-124
Report documents
-
Addendum
Ribociclib (breast cancer, adjuvant treatment) – Addendum to Project A24-124
Dossier assessment
Indication:
Adjuvant treatment of patients with HR-positive, HER2-negative early breast cancer at high risk of recurrence
Result of dossier assessment:
- Premenopausal women: added benefit not proven
- Postmenopausal women: hint of lesser benefit
- Men: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2025-06-05 A G-BA decision was published.
Project details
- Project no.
- A25-51
- Commission
- Commission awarded on 23.04.2025 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
- https://doi.org/10.60584/A25-51_en
Connected Projects
-
Dossier assessment
Ribociclib (breast cancer, adjuvant treatment) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed